TransThera Sciences (Nanjing), Inc. announced the successful completion of its new H-share placement on 21 April 2026. A total of 5.09 million H shares were placed with no fewer than six professional or institutional investors at HK$57.03 per share, satisfying all conditions under the placing agreement.

The transaction raised gross proceeds of HK$290.00 million, with net proceeds of HK$282.15 million after commissions and expenses, translating into a net issue price of HK$55.49 per share.

Management plans to allocate approximately HK$160.83 million (57%) to R&D—primarily the clinical development of core asset Tinengotinib across multiple oncology indications and further work on TT-00973. Roughly HK$93.11 million (33%) is earmarked for Tinengotinib manufacturing and commercial rollout on the mainland, including team build-out and marketing activities, while the remaining HK$28.21 million (10%) will support working capital and general corporate purposes.

The new shares represent 1.67% of the company’s pre-placement H-share base and expand total issued shares to 404.08 million. Post-placement, H-share holders account for 76.43% of issued capital (up from 76.13%), with no placee becoming a substantial shareholder. Core connected persons’ combined stake diluted marginally to 32.38% from 32.80%.

The board is chaired by founder and CEO Dr. Frank Wu; the announcement was released in Hong Kong on 21 April 2026.